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Summary:
The association of graft-versus-host disease (GVHD)
with lower relapse rates following allogeneic bone mar-
row transplantation (BMT) in humans led us to analyse
post HLA-identical BMT derived anti-host cytotoxic Τ
cells (CTL) for their putative anti-Ieukemic activity. To
establish whether graft-versus-host (GVH) and graft-
versus-leukemia (GVL) activities are separate, CTL
lines were generated at different time points post-BMT
from three patients suffering from acute GVHD. These
CTL lines, which exhibited lysis of host normal lym-
phocytes and neoplastic cells, were analysed at the
clonal level. Three functionally different types of clones
were characterized: clones directed at host specific
minor Histocompatibility (mH) antigens which are
shared by patient's periphera! blood lymphocytes (PBL)
and leukemic cells; clones recognizing only host PBL
but not host leukemic cells; and putative GVL clones
directed at patient's neoplastic cells only. These data
could explain the long controversies on dissection of
GVH and GVL activities. Our results demonstrate that
GVH and GVL activities can be dissected, while non-
separable effector cells which exhibit both activities do
exist as well.
One of the major obstacies in allogeneic bone marrow
transplantation (BMT) is the oecurrence of graft-
versus-host disease (GVHD).' Τ cell depletion of the
donor bone marrow inoculum shows a reduetion in the
ineidence and severity of GVHD but an increase in
relapse rate. Mature Τ cells in this donor bone marrow
inoculum vital for graft aeeeptance and responsible for
GVHD are probably also needed to eliminate residual
leukemic cells: the graft-versus-leukemia (GVL)
effect.2·3 Α substantial number of experimental animal
modeis indicate a GVL effect of allogeneic BMT.4·5
Although controversial, mouse data support the notion
that the GVL reaction can be distinguished from the
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GVH reactivities. Bortin et al.6 were the first to
demonstrate that GVL reaction could be induced by
alloimmunization while avoiding GVHD. In humans
several clinical trials have suggested a direct relation-
ship between the GVL effect and acute and chronic
GVHD.7-8 However, clinical data from Butturini et
al? and Horowitz et al.2 support a GVL effect inde-
pendent of GVHD that is altered by Τ cell depletion.
To our knowledge, the only in vitro result in humans
demonstrating that the GVL and GVHD effect may at
least partially be separable, is the Isolation of cytolytic
Τ cells from normal donors recognizing allogeneic
leukemic cells.9 1 0
We analysed post-BMT derived CTL lines from
three patients transplanted for acute lymphoblastic Τ
cell leukemia to ascertain whether separate popula-
tions of Τ cells in the bone marrow inoculum are
responsible for the anti-host and anti-leukemic activ-
ities.
Patients and methods
Three patients reeeived bone marrow grafts from their
HLA identical siblings. Acute GVHD was noted in all
three patients. Blood samples were collected from the
reeipient at the time neoplastic cells were present,
pre-BMT, at different time points post-BMT, and from
the healthy sibling donor. CTL lines were generated as
described earlier in detail." Briefly, post-BMT cells
(i.e. donor derived) are stimulated with patient's pre-
BMT PBL. The CTL lines were further expanded by
weekly Stimulation with reeipient pre-BMT EBV-
lymphoblastoid cell lines (EBV-LCL) and donor PBL.
Cytotoxic activity of the Τ cell lines and clones was
tested in a Standard l 5Cr release assay at different
effector/target cell ratios. As target cells we used
phytohaemagglutinin stimulated PBL (i.e. PHA blasts)
of donor and reeipient, EBV-LCL of donor and reeipi-
ent, and patient's leukemic cells (thawed and
preineubated overnight in RPMI 1640 supplemented
with 15% human serum). Specific lysis was calculated
as described." The CTL lines were analysed for
expression of CD4, CD8 and the NK markers CD 16
and CD56. Cloning, with or without CD4 depletion
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(ι e sorting the CD8 positive population), of the CTL
lines at 100, 30, 10, 3 and 1 cell/well was carned out
After reasonable growth was obtained, each individual
cional population was assayed for cytotoxicity on
recipient PHA bldsts and leukemic cells All positive
clones were further expanded enabling broader func-
tional analyses.
Results
Figure 1 shows that post-BMT denved CTL lines from
patients 1 and 2 lysed both normal and neoplastic cells
of the host as early as day 35 after BMT, while from
patient 3, such CTL lines were generated lrom day 100
after BMT In all three cases, the lysis was found to be
patient specific as no lysis was observed when donor
cells were used as target cells Only in the case of
patient 3 some EBV specific lysis became apparent
Subsequently, one CTL hne of each patient was used
for cloning the CTL hne of day 100, 35 and 100
post-BMT from patients 1, 2 and 3 respectively These
CTL lines ΔΚ negative (or the NK markers CD16 and
CD56 and do not lyse any of the Ν Κ sensitive target
cell lines Daudi, HL60 or K562 (data not shown)
Cloning at different seeding concentrations per well of
the CTL lines was repeated at least twice Table 1,
which IS representative of a sencs of expenments,
shows that independent ol the number of cells seeded
per well, three functionally difterent types of clones can
be isolated from each of the three patients' CTL lines
First, a large number of 'dual' positive clones elimin-
ating both patient's normal and neoplastic cells were
found Second, ciones directcd at host PBL only, and
third, host leukemic specihc clones weie isolated
Further expansion of these clones yielded stable 'duaF
positive and 'Single' anti-host directed clones The host
specihc leukemia directed clones appeared, however,
to be unstable and seemed to lose their activity in time
in culture
Patient 1
+40 +60
Days post BMT
+ 100 + 180
{•igure 1 Cytotoxicity pattern of post-BMT denved CTL lincs ot patients 1 2 and 3 (B) host PHA (^) host EBV-LXL (D) donor PHA
(Ä) donor EBV-LCL ( ) host Itukcmid
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Table I Cytolytic pattcrns of GVH and GVL spccific Τ ccll cloncs AcknowledgementS
Patient 1
100 c/w·1
30 c/w
Patient 2
10 c/w
3 c/w
Patient .?
0.3 c/w
IOOPlb
1OOP23
100L1
3OPI2
3OP3
30L29
D l
Η 9
L15
D2
H l
L4
FA46
KA43
GA22
Pll.i blast
W
74
0
80
58
4
95
89
3
99
95
->
38
41
11
rennet eells
Leuketme ce/h
94
0
59
89
0
89
48
1
31
40
->
24
28
14
44
a Number of cclls platcd per well
h Clonc (JcMgnalion
LPcrccntagc specific lysis
Discussion
Our data clearly show. by analysis of post-BMT
lymphocytes from threc patienis, that effector cells,
potentially representing GVH and GVL activities, can
be identified /'/; vitro. These activities are displayed by
Τ cells since no NK-likc characteristics were observed.
The possibilily of induced LAK activity is almost
negligible because of our eulture conditions. An expla-
nation for the controversies in dissecting GVH and
GVL activities is that not only GVH and GVL specific
clones were isolated but also clones reactive with
ligands shared by host PBL and leukemic cells. Char-
aclcrizalion of these 'dual' functional cloncs, directed
at host specific mH antigens which are expressed on
both patient's PBL and leukemic cells, is in agreement
with recent observations in our laboratory.12 Because
we did not fest our clones for their clonality at a
molecular level, it is possible that the last type of clones
are a summation of clones displaying lysis on
ncoplastic and normal patient's cclls. On the other
hand, our in vitro analysis is compatible with results
obtained in the mouse. Truitt et al. '·' described separ-
ate as "well as overlapping GVL and GVH reactive cell
populations. At present \vc are aiming to obtain stable
GVL clones. in order to establish whether these clones
show unique or broad anti-leukemic activity, and
whether they are directed al mH antigens with limited
tissue distribution or against truh leukemia associated
antigens. The fact that we are able to isolate Single
GVL directed Τ cell cloncs ma> contnbute to a further
understanding of possible effector cells of GVL. and
hopefully may lead to nev\ approaches for potentiating
anti-leukemic reactivity without inducing severe
GVHD.
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